This Month’s Focus: Particle Characterization
Quality requirements for cascade impactors assigned to batch release testing of a specific drug product; Part I: A grassroots look
The thesis presented here is that questions about accuracy and uncertainty of cascade impactor results have not been articulated by the inhaler testing community and that, consequently, producers today hold their cascade impactors to quality criteria that may be neither necessary nor sufficient for a confident batch release decision.
General Features
Dry powder inhalers—More than 170 years of development; Where to next?
The earliest reference to therapeutic dry powder inhalation may also be the earliest reference to “engineered particles,” dating from 1849, in London. Since the 1950s, the pace of dry powder inhaler (DPI) development has been astounding.
Back Page: Type of grass pollen, not total pollen count, may be useful for people with allergies
PollerGEN, an interdisciplinary group of researchers based in the United Kingdom, has published findings in Nature Ecology & Evolution, indicating that the species of grass pollen may have more impact than total pollen count on people who are affected by grass allergies.
Cross-Industry Organizations: The Aerosol Society:
DDL2019—Celebrating 30 years of the Drug Delivery to the Lungs Conference
Scientific lectures will look to the future, exploring major themes such as “The Future of the Planet— Pollution and the Environment,” with particulate matter air pollution being arguably the most significant environmental hazard to human health.
Previewing the Siminhale International Conference
The Siminhale International Conference “Current Challenges and Future Opportunities for Inhalation Therapies. A Cross-Disciplinary Perspective” will be held September 30-October 2, 2019 in Athens, Greece.
Previewing the 8th MVIS Symposium and Workshop
The 8th Medicon Valley Inhalation Symposium and Workshop will take place October 7-10, 2019 in Lund, Sweden. Participants may register for either or both events.
A preview of the 2019 AIT Annual Meeting
The Association of Inhalation Toxicologists will hold their annual meeting October 14-16, 2019 in Brighton, UK.
October Content
Technology selection in capsule-based inhalation product development
An updated look at solid-state physicochemical characterization and microscopy of particles in dry powder inhalers
Back Page: The first map of human lung and airway cells
Cross-Industry Organizations: The Respiratory Drug Delivery Conferences
A preview of AAPS PharmSci360
Previewing the 30th Drug Delivery to the Lungs (DDL)
Issue Focuses
January: Reference and Buyer’s Resource
February: Product Development/ Contract Testing
April: Instruments
June: Nasal Delivery/Nebulizers
August: Particle Characterization
October: Devices
December: Quality/Compliance
Vicki Schuman
1155 Northland Drive
St. Paul, MN 55120
651-287-5600
Fax 651-287-5650
vschuman@cscpub.com
Inhalation Article Guidelines
Technical article requirements
The article should be technical and educational, but not promotional. It must be new, not previously published and must be at least 50% different from your previous articles or other articles you are simultaneously developing on the same subject.
All discussions of products or technologies must be in an unbiased, non-promotional, educational manner. If your article discusses products that have been commercialized or are in development, please be aware of the following: Inhalation takes a very limited approach in discussing products, usually listing only product name, delivered drug name and company name, unless a description is provided by the particular company that owns a product, such as in a case study article or product news release. In that way, each company can choose the information it wishes to discuss or disclose about its own products, rather than being discussed by an outside party with no ability to comment prior to publication. However, if an article is a case study, presentation of a novel technology or news article written by the owner company or its representative such as a scientist or consultant, we are happy to consider all information or data they wish to disclose, provided it is presented in a fair-balanced manner. Also, please avoid discussing product or development costs and do not make cost comparisons.
The article should be 2,500-3,500 words and must include at least five references or items for recommended reading.
We encourage images and/or data tables and have space for three or four of them. We’re flexible about that number so let us know if you need more image space. We also like to publish an additional photo or illustration at the beginning of the article. Images should be sent as separate files that meet the following specifications: high resolution, 300 dpi at a size of 7 x 7 inches and in only JPG, TIF or EPS formats.
Please be aware, due to copyrights, if you use figures or tables from articles that have been previously published in other journals, you must obtain permission from those journals in order to use the images. If you are an author on the published article in question, you may still need permission but there should be no fees from the other journal. If you are not an author and the other journal wants to charge you fees for usage, please contact us before proceeding. We do not want authors incurring costs in order to publish in Inhalation and there may be alternate approaches to citing information that could be used. Also, “open journals” do not charge for image use. If you have any questions or concerns, please contact us.
Editorial board review and production
All of our articles are peer-reviewed and must be accepted by our editorial board or a designated reviewer in order to be published. When you send us the article, it will go to a member of the board and we will coordinate communication between you. Once an article is accepted, we handle production and you will see the final article in layout before it goes to print or is published in the digital edition.
Contract Testing
Excipients
